Vaccines

PopVax Goes Clinical

PopVax founder Soham Sankaran announces that its broadly protective COVID-19 vaccine candidate PVX-001 entered a first-in-human Phase I trial in Melbourne, with 14 participants dosed and no serious adverse events as of 6 October 2026, and describes the company's full-stack approach from computational protein design to in-house mRNA manufacturing.

Announcement · Biotech · Vaccines · Clinical Trials